225.14
price down icon1.05%   -2.40
after-market After Hours: 226.00 0.86 +0.38%
loading
Abbvie Inc stock is traded at $225.14, with a volume of 5.46M. It is down -1.05% in the last 24 hours and up +0.89% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$227.54
Open:
$227.62
24h Volume:
5.46M
Relative Volume:
1.02
Market Cap:
$397.72B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
107.14
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
-1.55%
1M Performance:
+0.89%
6M Performance:
+16.35%
1Y Performance:
+18.84%
1-Day Range:
Value
$224.04
$228.00
1-Week Range:
Value
$224.04
$229.86
52-Week Range:
Value
$163.81
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
11:01 AM

AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect - TradingView

11:01 AM
pulisher
05:00 AM

Allergan Aesthetics (NYSE: ABBV) marks BOTOX Day Nov 19 with $25,000 sweepstakes - Stock Titan

05:00 AM
pulisher
12:32 PM

AbbVie’s HIV Treatment Study Update: Key Insights for Investors - TipRanks

12:32 PM
pulisher
09:27 AM

AbbVie's Autoimmune Drug Rinvoq Achieves Endpoints In Two Replicate Phase 3 Vitiligo Studies - Nasdaq

09:27 AM
pulisher
09:15 AM

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo - Investing News Network

09:15 AM
pulisher
09:05 AM

United States Biotechnology Market 2025: Industry - openPR.com

09:05 AM
pulisher
08:56 AM

AbbVie (ABBV) Reports Promising Results from Phase 3 Studies on RINVOQ for Vitiligo - GuruFocus

08:56 AM
pulisher
08:11 AM

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo - PR Newswire

08:11 AM
pulisher
07:18 AM

Daymark Wealth Partners LLC Buys 2,276 Shares of AbbVie Inc. $ABBV - MarketBeat

07:18 AM
pulisher
07:17 AM

World Investment Advisors Has $19.33 Million Holdings in AbbVie Inc. $ABBV - MarketBeat

07:17 AM
pulisher
06:46 AM

Analyst IMS Investment Management Services Ltd. Lowers Position in AbbVie Inc. $ABBV - MarketBeat

06:46 AM
pulisher
06:30 AM

AbbVie Inc. $ABBV Shares Sold by L.M. Kohn & Company - MarketBeat

06:30 AM
pulisher
05:47 AM

Biltmore Family Office LLC Sells 2,930 Shares of AbbVie Inc. $ABBV - MarketBeat

05:47 AM
pulisher
05:33 AM

Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 2025Portfolio Update Report & Breakout Confirmation Trade Signals - newser.com

05:33 AM
pulisher
Oct 28, 2025

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Clinical Overview, Companies, Therapeutic Assessment, Treatment Approaches, Pipeline Insights | AbbVie, Sanofi - Barchart.com

Oct 28, 2025
pulisher
Oct 28, 2025

AbbVie: Deep Discount Before Earnings (NYSE:ABBV) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM - PR Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool

Oct 28, 2025
pulisher
Oct 28, 2025

Mizuho Markets Americas LLC Decreases Stock Holdings in AbbVie Inc. $ABBV - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Howard Capital Management Inc. Acquires 7,160 Shares of AbbVie Inc. $ABBV - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

AbbVie Inc. $ABBV Shares Acquired by Clark Asset Management LLC - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Logan Capital Management Inc. Lowers Stake in AbbVie Inc. $ABBV - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Will AbbVie Inc. stock attract more institutional investorsEarnings Overview Summary & Capital Protection Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock attract analyst upgrades2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest - Barchart.com

Oct 27, 2025
pulisher
Oct 27, 2025

AbbVie Defends Challenge Of Colorado's Discount Drug Law - Law360

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock withstand economic slowdownEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock extend growth storyPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock surprise markets with earningsPortfolio Growth Summary & Real-Time Chart Pattern Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock a buy on dips2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock resilient to inflationJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Teacher Retirement System of Texas Lowers Stake in AbbVie Inc. $ABBV - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Ophthalmic Drugs Market Set for Dynamic Growth with Key Players Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Fish Skin Disease Market to Witness Remarkable Growth With GSK - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Transcend Capital Advisors LLC Trims Position in AbbVie Inc. $ABBV - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Bessemer Group Inc. Acquires 12,455 Shares of AbbVie Inc. $ABBV - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

Whipplewood Advisors LLC Sells 1,240 Shares of AbbVie Inc. $ABBV - MarketBeat

Oct 27, 2025
pulisher
Oct 27, 2025

How AbbVie Inc. stock performs in rising dollar environmentWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

How sentiment analysis helps forecast AbbVie Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Why AbbVie Inc. (4AB) stock stays on top picksPortfolio Risk Summary & Technical Pattern Alert System - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

AbbVie Inc. $ABBV Stake Increased by Envestnet Asset Management Inc. - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

AbbVie Inc. $ABBV Position Boosted by Oppenheimer Asset Management Inc. - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

AbbVie Inc. $ABBV Shares Sold by Nisa Investment Advisors LLC - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

AbbVie Inc. $ABBV Shares Purchased by Stegent Equity Advisors Inc. - MarketBeat

Oct 26, 2025
pulisher
Oct 26, 2025

AbbVie Inc. $ABBV Position Reduced by Kornitzer Capital Management Inc. KS - MarketBeat

Oct 26, 2025
pulisher
Oct 25, 2025

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance

Oct 25, 2025
pulisher
Oct 25, 2025

AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$186.60
price down icon 0.18%
drug_manufacturers_general NVS
$121.80
price down icon 1.32%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
$291.77
price down icon 0.11%
Cap:     |  Volume (24h):